SCHEMBL3841951

SCHEMBL3841951

O=c1ccc(-c2ccccc2)nn1Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.78
▸ SMN1; SMN2 Q16637 2/20 0.78
▸ KMT2A Q03164 4/20 0.55
▸ POLB P06746 2/20 0.55
▸ MGLL Q99685 1/20 0.54
▸ ABHD6 Q9BV23 1/20 0.54
▸ MEN1 O00255 3/20 0.53
▸ PDE4A P27815 1/20 0.53
▸ PDE4B Q07343 1/20 0.53
▸ PDE4C Q08493 1/20 0.53
▸ PDE4D Q08499 1/20 0.53
▸ CHEK1 O14757 1/20 0.49
▸ NEK2 P51955 1/20 0.49
▸ LIMK1 P53667 1/20 0.49
▸ TYRO3 Q06418 1/20 0.49
▸ CLK4 Q9HAZ1 1/20 0.49
▸ MET P08581 3/20 0.47
▸ GABRA1 P14867 1/20 0.47
▸ GABRB2 P47870 1/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470365 0.90 MAPT (0.77) MAPTSMN1; SMN2KMT2APOLBMGLL
SCHEMBL2470591 0.90 MAPT (0.77) MAPTSMN1; SMN2KMT2APOLBMEN1
SCHEMBL4129601 0.89 MAPT (0.69) MAPTSMN1; SMN2KMT2APOLBMGLL
SCHEMBL12194158 0.89 MAPT (0.69) MAPTSMN1; SMN2KMT2APOLBMGLL
SCHEMBL1949173 0.87 MAPT (0.70) MAPTSMN1; SMN2KMT2APOLBMEN1
SCHEMBL11140135 0.81 POLB (0.74) MAPTSMN1; SMN2KMT2APOLBMEN1
SCHEMBL3117740 0.80 MAPT (0.58) MAPTSMN1; SMN2KMT2APOLBMEN1
SCHEMBL3117728 0.80 MAPT (0.58) MAPTSMN1; SMN2KMT2APOLBMEN1
SCHEMBL3840345 0.80 POLB (0.57) MAPTSMN1; SMN2KMT2APOLBMGLL
SCHEMBL4134359 0.79 MAPT (0.64) MAPTSMN1; SMN2KMT2APOLBMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314087-B2 Nitrogen-containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2012-11-20 — — US disclosed
US-8314087-B2 Nitrogen-containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2012-11-20 — — US disclosed
EP-2114898-A2 NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS Amgen Inc. (US) 2009-11-11 — — EP disclosed
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2008-11-13 — — US disclosed
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2008-11-13 — — US disclosed
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2008-11-13 — — US disclosed
WO-2008103277-A2 NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS AMGEN INC. (US) 2008-08-28 — — WO disclosed
WO-2008103277-A2 NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS AMGEN INC. (US) 2008-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use HGF, HGFAC, MET MAPT 3170/4885SMN1; SMN2 864/4885KMT2A 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback